Health and Medicine

News about UB’s health sciences programs and related community outreach. (see all topics)

Researchers to test blocking ‘hypermutations’ in deadly bacteria
6/16/22
UB receives $4 million from NIAID to develop new treatments that prevent 'hypermutations' in antibiotic-resistant bacteria.
Guthrie Symposium brings together researchers, families to discuss advances in newborn screening
6/16/22
UB/Oishei symposium June 28 for researchers and families of children with genetic diseases will celebrate Buffalo’s legacy as the birthplace of newborn screening.
Biochemists use proteins to change how neurons communicate
6/15/22
In a new study, scientists detail how they coaxed excitatory neurons to release neurotransmitters usually produced by inhibitory neurons.
UB receives $550,000 to provide dental care to people who are homeless, uninsured in WNY
6/15/22
The care will be delivered through the UB S-Miles To Go program using the university’s mobile dental clinics.
UB receives nearly $13 million to improve quality of HIV research around world
6/15/22
The seven-year grant is the third contract awarded to UB to lead a clinical pharmacology quality assurance program for NIH-funded labs.
UB-led study presents critical step forward in understanding Parkinson’s disease and how to treat it
6/9/22
Study found a method to differentiate human induced pluripotent stem cells (iPSCs) to A9 dopamine neurons (A9 DA), which are lost in Parkinson’s disease.
How might chimeric, droplet-forming proteins contribute to cancer?
6/8/22
A review article highlights the latest science in this field, focusing on protein droplets termed, “ectopic condensates."
NIDCR director to deliver lecture on state of oral health at UB
6/8/22
NIDCR director Rena D’Souza will visit UB to deliver a report on the status of oral health in the U.S. and discuss the importance of equity, diversity and inclusion within the biomedical sciences.
Pfizer chooses the Jacobs School for pediatric study of Paxlovid
5/27/22
Paxlovid, the COVID-19 medicine developed by Pfizer, is being evaluated in Western New York in children who are symptomatic with COVID-19 infection, and who are at risk of progression to severe disease.
Study: Antiviral gene known to block HIV also shows potent activity against SARS-CoV-2
5/26/22
In the ‘eternal arms race’ between pathogen and host, cells employ the same gene to fight both SARS-CoV-2 and HIV, revealing new avenues for potential therapies.

Next> <Previous